Plain-English translation of NCT07629115 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →This is a follow-up study for people who already received IPS101A, an experimental gene therapy, in an earlier trial for severe Parkinson's disease. Researchers want to understand how safe this treatment is over the long term and whether its benefits continue to work. You would be monitored with regular check-ups to track your health.
Gene therapies are new and need careful, long-term monitoring to make sure they remain safe and continue to help patients. This study ensures that the benefits people experienced don't fade away and watches for any delayed side effects.
You likely qualify if…
You likely don't qualify if…
As a participant, you would return for regular check-up visits to allow researchers to monitor your health and assess how you are doing over time. These visits will help doctors understand whether the gene therapy continues to be safe and effective for your Parkinson's symptoms. The study is designed to follow you long-term, so your commitment to attending scheduled appointments is important.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
South Korea
Enrollment target
~6 participants
Started
May 2026
Primary completion
July 2031
Age range
50 Years – 80 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
ChoLong Park
Innopeutics Corporation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.